Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Gene signature associated with benign neurofibroma transformation to malignant peripheral nerve sheath tumors.

Martínez M, Sorzano COS, Pascual-Montano A, Carazo JM.

PLoS One. 2017 May 24;12(5):e0178316. doi: 10.1371/journal.pone.0178316. eCollection 2017.

2.

Molecular profiles of neurofibromatosis type 1-associated plexiform neurofibromas: identification of a gene expression signature of poor prognosis.

Lévy P, Bièche I, Leroy K, Parfait B, Wechsler J, Laurendeau I, Wolkenstein P, Vidaud M, Vidaud D.

Clin Cancer Res. 2004 Jun 1;10(11):3763-71.

3.

SOX9 expression increases with malignant potential in tumors from patients with neurofibromatosis 1 and is not correlated to desert hedgehog.

Carbonnelle-Puscian A, Vidal V, Laurendeau I, Valeyrie-Allanore L, Vidaud D, Bièche I, Leroy K, Lantieri L, Wolkenstein P, Schedl A, Ortonne N.

Hum Pathol. 2011 Mar;42(3):434-43. doi: 10.1016/j.humpath.2010.02.020. Epub 2010 Dec 28.

PMID:
21193222
4.

Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors.

Beert E, Brems H, Daniëls B, De Wever I, Van Calenbergh F, Schoenaers J, Debiec-Rychter M, Gevaert O, De Raedt T, Van Den Bruel A, de Ravel T, Cichowski K, Kluwe L, Mautner V, Sciot R, Legius E.

Genes Chromosomes Cancer. 2011 Dec;50(12):1021-32. doi: 10.1002/gcc.20921. Epub 2011 Aug 24.

PMID:
21987445
5.

Transgenic mice overexpressing neuregulin-1 model neurofibroma-malignant peripheral nerve sheath tumor progression and implicate specific chromosomal copy number variations in tumorigenesis.

Kazmi SJ, Byer SJ, Eckert JM, Turk AN, Huijbregts RP, Brossier NM, Grizzle WE, Mikhail FM, Roth KA, Carroll SL.

Am J Pathol. 2013 Mar;182(3):646-67. doi: 10.1016/j.ajpath.2012.11.017. Epub 2013 Jan 13.

6.

Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours.

Subramanian S, Thayanithy V, West RB, Lee CH, Beck AH, Zhu S, Downs-Kelly E, Montgomery K, Goldblum JR, Hogendoorn PC, Corless CL, Oliveira AM, Dry SM, Nielsen TO, Rubin BP, Fletcher JA, Fletcher CD, van de Rijn M.

J Pathol. 2010 Jan;220(1):58-70. doi: 10.1002/path.2633.

7.

Subclassification of nerve sheath tumors by gene expression profiling.

Holtkamp N, Reuss DE, Atallah I, Kuban RJ, Hartmann C, Mautner VF, Frahm S, Friedrich RE, Algermissen B, Pham VA, Prietz S, Rosenbaum T, Estevez-Schwarz L, von Deimling A.

Brain Pathol. 2004 Jul;14(3):258-64.

PMID:
15446580
8.

Whole-exome sequencing of breast cancer, malignant peripheral nerve sheath tumor and neurofibroma from a patient with neurofibromatosis type 1.

McPherson JR, Ong CK, Ng CC, Rajasegaran V, Heng HL, Yu WS, Tan BK, Madhukumar P, Teo MC, Ngeow J, Thike AA, Rozen SG, Tan PH, Lee AS, Teh BT, Yap YS.

Cancer Med. 2015 Dec;4(12):1871-8. doi: 10.1002/cam4.551. Epub 2015 Oct 3.

9.

Aberrant demethylation and expression of MAGEB2 in a subset of malignant peripheral nerve sheath tumors from neurofibromatosis type 1.

Nobeyama Y, Nakagawa H.

J Dermatol Sci. 2016 Feb;81(2):118-23. doi: 10.1016/j.jdermsci.2015.11.004. Epub 2015 Nov 28.

PMID:
26642794
10.

Neurofibroma and schwannoma.

Ferner RE, O'Doherty MJ.

Curr Opin Neurol. 2002 Dec;15(6):679-84. Review.

PMID:
12447105
11.

Tamoxifen inhibits malignant peripheral nerve sheath tumor growth in an estrogen receptor-independent manner.

Byer SJ, Eckert JM, Brossier NM, Clodfelder-Miller BJ, Turk AN, Carroll AJ, Kappes JC, Zinn KR, Prasain JK, Carroll SL.

Neuro Oncol. 2011 Jan;13(1):28-41. doi: 10.1093/neuonc/noq146. Epub 2010 Nov 12.

12.

Characterization of the somatic mutational spectrum of the neurofibromatosis type 1 (NF1) gene in neurofibromatosis patients with benign and malignant tumors.

Upadhyaya M, Han S, Consoli C, Majounie E, Horan M, Thomas NS, Potts C, Griffiths S, Ruggieri M, von Deimling A, Cooper DN.

Hum Mutat. 2004 Feb;23(2):134-46.

PMID:
14722917
13.
14.

Differentially expressed genes in neurofibromatosis 1-associated neurofibromas and malignant peripheral nerve sheath tumors.

Holtkamp N, Mautner VF, Friedrich RE, Harder A, Hartmann C, Theallier-Janko A, Hoffmann KT, von Deimling A.

Acta Neuropathol. 2004 Feb;107(2):159-68. Epub 2003 Dec 13.

PMID:
14673600
15.

MRI features in the differentiation of malignant peripheral nerve sheath tumors and neurofibromas.

Wasa J, Nishida Y, Tsukushi S, Shido Y, Sugiura H, Nakashima H, Ishiguro N.

AJR Am J Roentgenol. 2010 Jun;194(6):1568-74. doi: 10.2214/AJR.09.2724.

PMID:
20489098
16.

High-resolution DNA copy number profiling of malignant peripheral nerve sheath tumors using targeted microarray-based comparative genomic hybridization.

Mantripragada KK, Spurlock G, Kluwe L, Chuzhanova N, Ferner RE, Frayling IM, Dumanski JP, Guha A, Mautner V, Upadhyaya M.

Clin Cancer Res. 2008 Feb 15;14(4):1015-24. doi: 10.1158/1078-0432.CCR-07-1305.

17.

Intraparotid facial nerve neurofibroma in neurofibromatosis type 1.

Edizer DT, Hajizade Y, Karaman E, Cansiz H.

J Craniofac Surg. 2011 May;22(3):1118-9. doi: 10.1097/SCS.0b013e3182108f22.

PMID:
21586962
18.

Molecular profiling of malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1, based on large-scale real-time RT-PCR.

Lévy P, Vidaud D, Leroy K, Laurendeau I, Wechsler J, Bolasco G, Parfait B, Wolkenstein P, Vidaud M, Bièche I.

Mol Cancer. 2004 Jul 15;3:20.

20.

Adhesion molecule L1 is down-regulated in malignant peripheral nerve sheath tumors versus benign neurofibromatosis type 1-associated tumors.

Blessmann M, Gröbe A, Quaas A, Kaifi JT, Mistakidis G, Bernreuther C, Sauter G, Gros S, Rawnaq T, Friedrich R, Mautner VF, Smeets R, Heiland M, Schachner M, Izbicki JR.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Feb;113(2):239-44. doi: 10.1016/j.tripleo.2011.04.019. Epub 2011 Aug 11.

PMID:
22677742

Supplemental Content

Support Center